AbbVie: Cystitis, Interstitial trials

The registry lists 10 Cystitis, Interstitial studies with AbbVie as lead sponsor. 0 are open to participants now and 6 have results posted.

Phase 1 2Phase 2 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain SyndromeCompletedNCT02411110Phase 2Results posted
• A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's LesionsCompletedNCT02395042Phase 2Results posted
• A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis (IC) and Hunner's LesionsCompletedNCT01879683Phase 1Results posted
• Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial CystitisTerminatedNCT01824303Phase 2Results posted
• Double-Blind Placebo Controlled Study of Safety,Tolerability, and Efficacy of LiRIS® in Women With Interstitial CystitisTerminatedNCT01475253Phase 2Results posted
• Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder SyndromeCompletedNCT00919113Phase 2Results posted
• Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)CompletedNCT05141006Phase 2
• Safety Study of LiRIS in Interstitial Cystitis (IC) PatientsCompletedNCT01150565Phase 1
• A Pilot Clinical Investigation of the Efficacy and Safety of Uracyst® Versus Placebo in Patients With Interstitial Cystitis/Painful Bladder Syndrome.CompletedNCT00527917Phase 2
• Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial CystitisTerminatedNCT00380783Phase 2